A Phase II Study of Gefitinib Monotherapy as First-Line Treatment for Elderly Patients with Stage IIIB /IV Adenocarcinoma of the Lung
Phase 2
- Conditions
- Adenocarcinoma of the lung
- Registration Number
- JPRN-UMIN000006144
- Lead Sponsor
- Central Japan Lung Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
1) Concomitant serious medical conditions 2) Interstitial lung disease or pulmonary fibrosis detected by conventional computed tomography of the chest 3) Massive pleural or pericardial effusion or ascites that required drainage, superior vena caval syndrome or symptomatic brain metastasis 4) History of serious drug allergy 5) Previous radiotherapy to the primary tumor 6) Other concurrent active malignancy 7) Pregnancy or lactation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method